Biohaven Ltd. filed a Form 8-K on September 10, 2026, reporting that the U.S. Food and Drug Administration issued a partial clinical hold on September 4, 2026, pausing new patient enrollment in its BHV-7000 program pending additional nonclinical data on a specific metabolite, while also disclosing a license agreement with SK Biopharmaceuticals Co., Ltd. covering its Kv7 ion channel platform.
Key Highlights
- Partial clinical hold issued: The FDA issued a partial clinical hold letter on September 4, 2026, pausing new patient enrollment in the BHV-7000 program pending additional nonclinical data on a specific metabolite.
- Dosing continues: More than 600 already-randomized patients across the BHV-7000 program continue dosing; the hold applies to new enrollment only.
- BHV7000-303 unaffected on timing: Enrollment and randomization in BHV7000-303 were previously completed, and topline data remain on track for the second half of 2026.
- Metabolite significance uncertain: According to the filing, "the findings may be specific to rodents and not relevant to human safety," and over 1,200 participants have been dosed with BHV-7000 across the development program.
- License agreement signed: On August 26, 2026, Biohaven's subsidiary Biohaven Bioscience Ireland Limited entered into a License Agreement with SK Biopharmaceuticals Co., Ltd., granting SKBP an exclusive, royalty-bearing, worldwide license to Biohaven's Kv7 ion channel platform, including BHV-7000.
- HSR filing pending: Biohaven and SKBP are working on completion of the required Hart-Scott-Rodino submission before the license agreement can close.
Biohaven's BHV-7000 Program: Partial Clinical Hold and Kv7 Platform License
Biohaven Ltd. (NYSE:BHVN), incorporated in the British Virgin Islands and headquartered in New Haven, Connecticut, disclosed in its Item 8.01 filing that the FDA issued a partial clinical hold letter on September 4, 2026. The hold was prompted by insufficient information related to a specific metabolite of BHV-7000 observed in rodent testing, which the company said made it unable to fully assess risks of that metabolite to human subjects at this time. According to the filing, the company provided an update to global regulatory authorities as part of ongoing nonclinical characterization of certain metabolites, and the FDA then instructed the company to pause new enrollment until additional clarifying nonclinical studies are completed.
The filing specifies that the partial clinical hold applies only to new patient enrollment. Dosing continues for all patients already randomized across the BHV-7000 program, which the company reported to be more than 600 patients. BHV7000-303, described as one of two pivotal randomized, double-blind, placebo-controlled studies evaluating BHV-7000 in adults with refractory focal epilepsy, is fully enrolled and randomized. The filing states that topline data from BHV7000-303 remain on track for the second half of 2026. The company also reported that BHV7000-302 will continue dosing for already-randomized patients, and that the open-label extension study continues dosing as well. Biohaven disclosed it voluntarily applied this enrollment pause to its global sites outside the U.S.
Separately, the filing discloses that Biohaven Bioscience Ireland Limited, a wholly owned subsidiary, entered into a License Agreement with SK Biopharmaceuticals Co., Ltd. on August 26, 2026. Under the agreement, SKBP will receive an exclusive, royalty-bearing, worldwide license to Biohaven's Kv7 ion channel platform, including BHV-7000 and other covered compounds, effective upon closing. The filing states that all clinical and nonclinical data, including those related to the metabolite characterization submitted to global regulatory authorities, were fully disclosed to SKBP before the agreement was signed. Closing remains subject to completion of the required Hart-Scott-Rodino submission.
What Was Disclosed
Biohaven reported a September 4, 2026 FDA partial clinical hold pausing new BHV-7000 enrollment due to uncertain nonclinical metabolite findings, while confirming continued dosing for over 600 randomized patients and a worldwide license agreement with SK Biopharmaceuticals Co., Ltd. for its Kv7 platform.




Please wait processing your request...